MONMOUTH JUNCTION, N.J., April 7 /PRNewswire/ -- Tris Pharma, a specialty pharmaceutical company that develops innovativedrug delivery technologies, announced appointment of Mr. Peter Ciano to an important leadership position of Vice President of Corporate Development. Mr. Ciano had been working for Tris as a business development consultant
"As our technology gains wider acceptance for both Rx and OTC branded businesses, we are increasingly faced with the need for intelligent pursuit of the products and opportunities. Peter's solid analytical approach coupled with his deep understanding of pharmaceutical marketer's needs and health care provider's requirement for reimbursement makes him uniquely qualified to guide and lead Tris in this position," said Ketan Mehta, Founder and CEO of Tris Pharma.
"There are relatively few technology-based oral products that get attention of pharmaceutical marketers or create unique profile lending them for a true differentiation. Tris' portfolio of sustained release dosage forms in liquid, ODT/chewable, etc. that does not require swallowing really sets itself apart. That is the reason I am really excited to be leading this effort. Tris' management team has laid a solid foundation and I am looking forward to building on it," said Peter Ciano.
Peter has a diverse background including alumnus of Rutgers and Stanford executive education program. A pharmacist by training, he started his career as a retail pharmacist. After finishing his MBA in finance, he joined a boutique strategic management consulting firm and spent six plus years including last three years as Vice President. His clients included leading pharmaceutical firms such as Pfizer, Novartis, drug distribution companies and health system firms. Then he spent about six years at Kos Pharmaceuticals of which the last two years as Executive Director of Corporate Development and Business Planning prior to acquisition by Abbott Labs. While at Kos he played an important role in many business development transactions including a co-promotion with Takeda Pharmaceuticals and leading a cross-functional team charged with identifying para-IV settlement options in defense of Kos' key brand product. At Tris, Peter will lead all commercial efforts including business development, licensing, identifying growth opportunities and deal executions.
Most recently, Tris had announced FDA had approval two NDAs including first-ever 24-hour ER suspension. Tris has an active portfolio of more than 20 OTC and Rx products based on its proprietary technology.
About Tris Pharma:
Tris Pharma is a product-focused, specialty pharmaceutical company engaged in the research and development of innovative drug delivery technologies. Through its OralXR+ platform, Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse platform provides abuse-deterrence for opioids and other abuse-prone drugs. The company has more than 20 Rx and OTC products in development with pharmaceutical partners. Tris' R&D and manufacturing facilities are located in Monmouth Junction, New Jersey. For more information visit http://www.trispharma.com
SOURCE Tris Pharma
Subscribe to our Free Newsletters!
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...
Find out about travel shots or vaccination before you travel to your destination country. Travel ...
Hay fever is caused by allergy to pollen and is characterized by runny or blocked nose, sneezing, ...View All